Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.84 |
| ▸ | PDE6C | P51160 | 3/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.50 |
| ▸ | PDE2A | O00408 | 1/20 | 0.49 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.49 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.49 |
| ▸ | PDE6D | O43924 | 1/20 | 0.49 |
| ▸ | PDE8A | O60658 | 1/20 | 0.49 |
| ▸ | PDE9A | O76083 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | PDE6A | P16499 | 1/20 | 0.49 |
| ▸ | PDE6G | P18545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL147337 | 0.92 | PDE5A (1.00) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL29611957 | 0.86 | PDE5A (0.90) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL146830 | 0.86 | PDE5A (0.90) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL29357402 | 0.85 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL2693448 | 0.85 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL25013469 | 0.84 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL7964961 | 0.84 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL30199753 | 0.84 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL15111105 | 0.83 | PDE5A (0.77) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL7965731 | 0.83 | PDE5A (0.84) | PDE5APDE6CHDAC1HDAC6HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166662-A1 | Treatment of the insulin resistance syndrome | PFIZER INC. | 2003-09-04 | — | — | US | claimed |
| US-20020165237-A1 | Treatment of the insulin resistance syndrome | PFIZER INC. | 2002-11-07 | — | — | US | claimed |
| US-6967204-B2 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
| US-20040023989-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | FRYBURG DAVID A (US) | 2004-02-05 | — | — | US | disclosed |
| US-20030166662-A1 | Treatment of the insulin resistance syndrome | PFIZER INC. | 2003-09-04 | — | — | US | disclosed |
| US-20020165237-A1 | Treatment of the insulin resistance syndrome | PFIZER INC. | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166662-A1 | Treatment of the insulin resistance syndrome | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE6C 263/4885HDAC1 1044/4885 |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | PDE5A 4/4885PDE6C 40/4885HDAC1 1250/4885 |
| US-20040023989-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | PDE5A 4/4885PDE6C 40/4885HDAC1 1250/4885 |
| US-20020165237-A1 | Treatment of the insulin resistance syndrome | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE6C 224/4885HDAC1 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.